RxDoctor Payments Data

Mark Round, MD

Internal Medicine · Kissimmee, FLNPI 1265477640

Payments from drug & device makers

$8,989in general payments, 2019–2025

Across 505 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$1K
  • Boehringer Ingelheim$695
  • Pfizer$624
  • Amgen$375
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,960100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,989 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$108,154
Medicare patients
212
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$161,284
MounjaroTirzepatide121$135,988
JardianceEmpagliflozin97$117,318
FarxigaDapagliflozin Propanediol115$106,469
OzempicSemaglutide82$102,099
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$64,636
JanuviaSitagliptin Phosphate57$63,524
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$34,153
XareltoRivaroxaban28$31,538
LinzessLinaclotide33$28,061
TrulicityDulaglutide21$20,842
VascepaIcosapent Ethyl42$20,329
RybelsusSemaglutide15$19,796
Tresiba Flextouch U-100Insulin Degludec21$17,593
EntrestoSacubitril/Valsartan12$15,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$624$161,284134 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$1,930$156,865192 claims
Lilly USA, LLCMounjaro, Trulicity$336$156,831142 claims
Boehringer IngelheimJardiance, Spiriva Respimat$695$125,931109 claims
Novo NordiskOzempic, Rybelsus, Novolog$331$123,780108 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,305$79,135103 claims
MerckJanuvia$14$63,52457 claims
Johnson & JohnsonXarelto$142$31,53828 claims
AbbVieLinzess, Synthroid$1,073$30,02462 claims
NovartisEntresto$74$15,57712 claims
Hikma Pharmaceuticals USAEpinephrine$13$2,13811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →